SYNTHENA
Synthena is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases based on the modulation of RNA. Its proprietary tricyclo-DNA technology platform offers broad advantages over state of the art oligonucleotide chemistries for new RNA intervention strategies like splice switching, and other antisense approaches. Its most advanced preclinical drug development program focuses on Duchenne Muscular Dystrophy, a genetic disorder which affects 1/3,500 boys and which leads to death in early adulthood.
SYNTHENA
Industry:
Biotechnology Health Care Medical
Address:
Bern, Bern, Switzerland
Country:
Switzerland
Website Url:
http://www.synthena.com
Status:
Active
Contact:
+41(0) 31 631 4265
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress LetsEncrypt SSL By Default
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
G2 Therapies
G2 is a privately funded biotechnology company that develops and commercializes novel antibody-based therapies in inflammation and cancer.
Genome
Genome is a biotechnology company developing and commercializing DNA sequencing technology.
Mucosis
Mucosis is a clinical stage Dutch biotechnology company developing mucosal vaccines.
SIRENADE Pharmaceuticals
A drug development start-up company that uses an integrated system of molecular tools to develop novel small molecule inhibitors.
Spirogen
Spirogen is a clinical stage biotechnology company specialising in novel, sequence-selective, DNA minor groove-binding molecules with
Official Site Inspections
http://www.synthena.com
- Host name: cluster021.hosting.ovh.net
- IP address: 188.165.53.185
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Synthena"
Synthena – oligonucleotide based therapeutics – Treatment of …
Synthena AG is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases …See details»
Synthena - Crunchbase Company Profile & Funding
Synthena is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases based on the …See details»
Synthena AG - BioAlps
Avenue de Sécheron 15 1202 Geneva, Switzerland T +41 22 545 12 91. c/o BIOPÔLE SA Secteur Esplanade / Bâtiment Serine Route de la Corniche 8 1066 Epalinges, SwitzerlandSee details»
Synthena AG (SYN) - Brain Involvement in Dystrophinopathies …
Luis GARCIA is the lead contact for Synthena AG for co-ordination with project partners. Dr Dmitry Stetsenko. Position in Organisation Chief Scientific Officer. Profile Dmitry Stetsenko …See details»
Synthena AG - VentureRadar
Synthena is developing oligonucleotide based therapeutics primarily for the treatment of genetic neuromuscular diseases by using its tricyclo-DNA molecular platform Affiliation: Universität …See details»
Synthena - Overview, News & Similar companies | ZoomInfo.com
Who is Synthena. Synthena AG is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neur omuscular …See details»
Synthena AG Company Profile | Bern, BERN, Switzerland
Find company research, competitor information, contact details & financial data for Synthena AG of Bern, BERN. Get the latest business insights from Dun & Bradstreet.See details»
Synthena AG - Swiss Biotech
Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members, the association works to secure favorable framework …See details»
Synthena AG - Bern, Switzerland - bionity.com
Synthena is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases based on the …See details»
Synthena - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Synthena is a development stage biotechnology company aiming to develop and commercialize new life saving drugs.See details»
Synthena AG - startup.ch
Synthena AG: Synthena is developing oligonucleotide based therapeutics primarily for the treatment of genetic neuromuscular diseases by using its tricyclo-DNA molecular platform.See details»
Delving into the Latest Updates on Synthena AG with Synapse
Earlier in his career, he was CEO of GeneProt Inc., a US proteomics company; Mind NRG, a Swiss biotech in the field of CNS (which was acquired by Minerva Neurosciences); OncoEthix, …See details»
Oligonucleotide-based Therapeutics (Synthena) - Drug Targets
Oligonucleotide-based Therapeutics (Synthena), Initially developed by Synthena AG, Now, its global highest R&D status is Pending, Therapeutic Areas: Nervous System …See details»
☑️Synthena AG — Consulting Organization from
Synthena AG — Consulting Organization from Switzerland, has experience with Horizon 2020 (2014 - 2020), it`s involved in Health sectorSee details»
The 10th Oligonucleotide Therapy Approved: Golodirsen for …
A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ... Such compounds include a conjugated tricyclo modified …See details»
SQY managers – SQY Therapeutics
SQY Therapeutics followed in 2015 to test and evaluate molecules produced by Synthena. Christine Saulnier. Co-founder and strategic direction of SQY Therapeutics "My son Julien …See details»
Questions for Only Watch, Luc Pettavino and all the answers so far
Oct 18, 2023 Questions first arose 4 th October regarding the organization’s distribution of its charity funds and precisely how it has contributed to the research on Duchenne Muscular …See details»
Dirigeants SQY - SQY Therapeutics
Et SQY Therapeutics en 2015 pour tester et évaluer les molécules produites par Synthena. Christine Saulnier. Co-fondatrice et direction stratégique de SQY Therapeutics "Mon fils Julien …See details»
Research programme: oligonucleotide-based therapeutics
Feb 28, 2017 Synthena is developing tricyclo-DNA-based therapeutics for the treatment of Duchenne muscular dystrophy. The therapeutics will be developed using Synthena's ... If your …See details»
Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity …
Mar 6, 2020 Human plasma from healthy volunteers was obtained from the French Blood Donors Organization (Etablissement Français du Sang [EFS]). Mouse or human citrated …See details»